Abstract:The development of neutralizing anti-FVIII antibodies (inhibitors) is one major complication of FVIII protein replacement therapy in hemophilia A patients. Our previous study demonstrated that the induction of activated follicular helper T (Tfh) cells in FVIII null mice is critical for FVIII inhibitor development. Follicular regulatory T (Tfr) cells are a specialized subset of Foxp3 + T cells identified in the germinal center (GC) that can modulate Tfh cell activation of B cells and antibody development. However, the role of Tfr cells in controlling anti-FVIII inhibitor development in vivo is still unclear. Here, we explored the activation and induction of Tfr cells and their functions in anti-FVIII inhibitor development in FVIII-immunized mice. We first characterized the features of activated Tfr cells in the spleen of immunized FVIII null mice by flow cytometry analysis. Activated Tfr cells were defined as CD4 +Foxp3 +CD44 +CD62L -CXCR5 +PD-1 +. Tfr cells express a high level of transcription factor BCL6 and costimulatory receptor ICOS. Activated Tfr cells also express a high level of costimulatory receptor CTLA4, which is similar to non-Tfr effector Treg cells, but CD25 expression is low on Tfr cells. FVIII immunization increases the frequency and the absolute number of activated Tfr cells in the spleen of mice that produce inhibitors. The percentage of activated CXCR5 hiPD-1 hi Tfr cells within the CD4 population significantly increased in inhibitor-producing mice compared to saline-treated controls and non-inhibitor-producing mice (0.88 ± 0.2 %, 0.33 ± 0.16 %, and 0.36 ± 0.2%, respectively). The Tfh/Tfr ratio also significantly increased in FVIII inhibitor-producing mice, suggesting a preferential expansion of Tfh cells relative to Tfr cells in inhibitor-producing mice. Interestingly, similar to Tfh cells as we reported before, the emergence of Tfr cells correlated with titers of anti-FVIII inhibitors in FVIII immunized mice. This indicates that a functional relationship exists between Tfr cell activation and FVIII inhibitor production after FVIII immunization. Using Tfr deficient Foxp3-Cre Bcl6 fl/fl (BCL6FC) mice, we determined the role of Tfr cells in inhibitor generation in vivo. Loss of Tfr cells led to significantly decreased FVIII inhibitor levels, with FVIII inhibitor titers in BCL6FC mice markedly lower than in wild-type (WT) mice upon recombinant human full-length FVIII (rhFVIII, Kogenate 200 U/kg/week IV x4) immunization (24 ± 16 and 131 ± 114 BU/ml, respectively). However, the total anti-FVIII IgG titers were similar between the BCL6FC and WT groups, suggesting that Tfr cells help generate neutralizing anti-FVIII antibodies. FVIII immunization could still efficiently induce Tfh cell activation in BCL6FC mice. However, both GC Tfh cells and GC B cells were reduced in FVIII immunized BCL6FC mice, suggesting that Tfr cells promote FVIII-specific GC responses. To further investigate the regulatory function of Tfr cells on FVIII immune responses, mice with phosphatase Pten deficiency in Treg cells (Foxp3-Cre Pten fl/fl [PtenFC]), a model with augmented Treg and Tfr cells, were immunized with rhFVIII and anti-FVIII antibody titers were measured at 1 week after the 4 th weekly immunization. Of note, FVIII inhibitor titers (8.06 ± 8.6 BU/ml) were significantly lower than those in WT controls under the same immunization protocol. There were significant positive correlations between the inhibitor titers and total anti-FVIII IgG in the WT and PtenFC groups but not in the BCL6FC group after rhFVIII immunization. To confirm the important role of the Tfh/Tfr pathway in FVIII inhibitor development, we used CD4-Cre Bcl6 fl/fl (CD4-Bcl6-cKO) mice, a model with Bcl6 deficiency in all CD4 + T cells. As expected, none of the CD4-Bcl6-cKO mice developed detectable levels of FVIII inhibitors, demonstrating that the transcription repressor BCL6 is pivotal for FVIII inhibitor development. In conclusion, we found that FVIII immunization induces Tfr cell activation and expansion. Tfr cells have a dual function in regulating FVIII immune responses in mice, and the Tfh/Tfr pathway is essential for FVIII inhibitor development in hemophilia A mice.

A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development after Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.

The Immune Response to the fVIII Gene Therapy in Preclinical Models

Reduction of Inhibitor Titres by Infusion of FVIII Gene Transduced Tolerogenic Dendritic Cells in Haemophilic Mice

Transient Blockade of Icos Co-Stimulatory Pathways Induces Long-Term Tolerance to Factor Viii Following Nonviral Gene Transfer of Factor Viii Plasmid into Hemophilia A Mice.

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Anti-Cd3 Antibodies Modulate Anti-Factor Viii Immune Responses in Hemophilia Amice after Factor Viii Plasmid-Mediated Gene Therapy

Cd4(+)Foxp3(+) Regulatory T Cells Confer Long-Term Regulation of Factor Viii-Specific Immune Responses in Plasmid-Mediated Gene Therapy-Treated Hemophilia Mice

IL-15 Blockade and Rapamycin Rescue Multifactorial Loss of Factor VIII from AAV-transduced Hepatocytes in Hemophilia A Mice.

Elevated memory T‐cell conversion in a preclinical mouse model of hemophilia A

Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A

Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.

Reduction Of Factor Viii Inhibitor Formation With F.Viii-Pulsed Tolerogenic Dendritic Cells In The Murine Hemophilia A Model.

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor

Induction of Tolerance to Factor Viii Inhibitors by Gene Therapy with Immunodominant A2 and C2 Domains Presented by B Cells As Ig Fusion Proteins

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway

Anti-CD3 Antibodies Induce Tolerance to FVIII in Hemophilia A Mice after FVIII Plasmid-Mediated Gene Therapy (89.19)

The Impact of Gpiba on the Efficacy of Platelet-Targeted Fviii Gene Therapy in Hemophilia A with Pre-Existing Anti-Fviii Immunity

Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells

Transient Blockade Of The Inducible Costimulator Pathway Generates Long-Term Tolerance To Factor Viii After Nonviral Gene Transfer Into Hemophilia A Mice

The Tfh/Tfr Pathway Is Pivotal in FVIII Inhibitor Development in Mice